Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485)

PHASE2CompletedINTERVENTIONAL
Enrollment

650

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

May 31, 2014

Study Completion Date

September 30, 2014

Conditions
TuberculosisHIV Infections
Interventions
BIOLOGICAL

MVA85A/AERAS-485

Subjects received intradermal injection of MVA85A/AERAS-485 on Study Day 0, followed 6-9 months later by a booster injection of MVA85A/AERAS-485.

BIOLOGICAL

Placebo

Subjects received an intradermal injection placebo on Study Day 0, followed 6-9 months later by a booster injection of placebo.

Trial Locations (2)

7325

Hopital Aristide Le Dantec, Dakar

7925

University of Cape Town, Cape Town

Sponsors

Lead Sponsor

All Listed Sponsors
collaborator

University of Oxford

OTHER

collaborator

European and Developing Countries Clinical Trials Partnership (EDCTP)

OTHER_GOV

lead

Aeras

OTHER

NCT01151189 - Efficacy Against TB Disease, Safety, and Immunogenicity of MVA85A/AERAS-485 in HIV-Infected Adults (C-030-485) | Biotech Hunter | Biotech Hunter